mira.patel
TL4 Administrator Co-founder · Documentation · Manchester, UK
Co-founder and documentation lead. My job is turning good threads into maintained pages. If a topic keeps being re-asked, that is a documentation failure and I would like to hear about it. Background in technical writing for analytical instrument vendors.
Joined 16 May 2024 · last posted 4h · groups: staff, moderators, wiki-editors, regional-apac, trust-level-4
215Posts here
7Topics
0Solutions
2.3kLikes received
1kLikes given
33Badges
125Days visited
6.7kPosts read
Recent activity
Full stream-
Mobile reading experience on long topics Replied, post #3 · Meta › Site feedback · 28 Jul 2026 · 5 likes Logged, and thank you for the precise description. That is a wording problem rather than a logic problem — an empty state that says "no topics match both filters" is a…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #114 · Start Here › Welcome · 27 Jul 2026 · 9 likes This is the sort of exchange that makes the archive worth searching.
-
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #61 · Clinical › Bloodwork · 25 Jul 2026 · 0 likes That matches what I have seen, for whatever a single anecdote is worth.
-
Here for the analytics and not much else Replied, post #87 · Lounge › Introductions · 24 Jul 2026 · 0 likes Welcome from staff. Nothing is required of you here — no posting quota, no introduction, no declaration of background. The only thing we ask is that a claim about a…
-
Follow-up: Comparing two chromatograms from different laboratories, properly Replied, post #66 · Analytics › HPLC & UHPLC · 24 Jul 2026 · 7 likes This is the sort of exchange that makes the archive worth searching.
-
Submitting a sample: the process end to end Replied, post #106 · Sourcing › Independent verification · 24 Jul 2026 · 2 likes Picking up post #104: that is the part I would want checked first. Repeat testing: if you want to verify the same lot a second time, testing with a different service…
-
Follow-up: Reading an interaction checker output critically Replied, post #58 · Practice › Interactions · 21 Jul 2026 · 2 likes Oral medications with a narrow therapeutic index are the ones where that matters most. The interaction is about rate and timing rather than about the total absorbed, in…
-
Restarting after a long gap: what the labelling implies Replied, post #29 · Practice › Dosing & titration · 16 Jul 2026 · 23 likes Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #35 · Access › Insurance & coverage · 16 Jul 2026 · 15 likes Worth separating two things that post #31 runs together. Formulary changes happen on a published schedule, so a denial now may be answering criteria that change…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #30 · Access › Insurance & coverage · 15 Jul 2026 · 0 likes Nothing here is legal or medical advice, and appeal processes differ enough by jurisdiction and payer that specifics do not transfer.
-
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #3 · Clinical › Bloodwork · 15 Jul 2026 · 0 likes Time of day: some biomarkers vary across the day. Cortisol in the morning differs from cortisol in the evening. Comparing results from different times of day is…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #85 · Analytics › Home & field testing · 14 Jul 2026 · 5 likes Coming back to post #83, because the follow-up matters more than the original answer. The arithmetic on consumer-accessible tests is the easy part and it is where the…
Maintains 32 documents
- Semaglutide — referenceReview due 17 Apr 2027
- Retatrutide — referenceReview due 4 Dec 2026
- Liraglutide — referenceReview due 8 Mar 2027
- Orforglipron — referenceReview due 11 Jun 2027
- Oral semaglutide — referenceReview due 24 Jan 2027
- TB-500 — referenceReview due 3 Oct 2026
- Growth-hormone-releasing peptides (GHRP class) — referenceReview due 14 Mar 2027
- Tesamorelin — referenceReview due 21 Aug 2026
- Access notes: FranceReview due 10 May 2027
- Access notes: NetherlandsReview due 9 Aug 2026